China accounts for 66% of India's bulk drug imports in FY'17

Image
Press Trust of India New Delhi
Last Updated : Dec 19 2017 | 5:20 PM IST
India's bulk drug imports from top five countries stood at Rs 18,372.54 crore in 2016-17 with China accounting for 66 per cent, Parliament was informed today.
In a written reply in Lok Sabha, Minister of State, Chemicals and Fertilisers Mansukh L Mandaviya said the other four major countries from where India imports bulk drugs are Germany, the US, Italy and Singapore.
India's import of active pharmaceutical ingredients (API) from China stood at Rs 12,254.97 crore in 2016-17, while that from the US was at Rs 820.18 crore.
API import from Italy was at Rs 701.85 crore during the year under review, while the same from Germany and Singapore was at Rs 485.11 crore and Rs 422.01 crore respectively.
"It may be mentioned that most of the imports of bulk drugs/API (are) being done in the country because of economic considerations," Mandaviya said.
As India is a signatory to the WTO and TRIPs agreement, import restrictions have been removed, he added.
In 2015-16, India's total bulk drug imports from the top five countries were at Rs 21,225.97 crore and it was Rs 19,833.19 crore in 2014-15, the minister added.
Replying to another query, Mandaviya said the Department of Pharmaceuticals has asked medical device associations, healthcare industry bodies and relevant regulatory agencies to help in categorising medical devices.
The purpose is to categorise medical devices so as to have different trade margins for various categories for different segments, considering the vast diversity and the logistics required in delivering them to patients, he said.
"Industry has proposed that the total trade margins for medical devices could be capped to make quality medical devices affordable. Discussions on the issue with industry resulted in the need for categorisation," Mandaviya said, adding there has been no consensus on the issue.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Dec 19 2017 | 5:20 PM IST

Next Story